Publisher
Springer Nature Singapore
Reference156 articles.
1. Kaplan JB, Stein BL, McMahon B, Giles FJ, Platanias LC. Evolving therapeutic strategies for the classic Philadelphia-negative myeloproliferative neoplasms. EBioMedicine. 2016;3:17–25.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): myeloproliferative neoplasms (Version 1.2020). 2020.
3. Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635–42.
4. Economides MP, Verstovsek S, Pemmaraju N. Novel therapies in myeloproliferative neoplasms (MPN): beyond JAK inhibitors. Curr Hematol Malig Rep. 2019;14(5):460–8.
5. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94(4):599–610.